GeoffreyScottGilmartinMD
Pulmonology • Boston, MACritical Care Medicine, Pleural Disease
Attending Physician, Beth Israel Deaconess Medical Center Boston, MA Chief Development Officer Proteostasis Therapeutics Cambridge, MA
Dr. Gilmartin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
330 Brookline Ave
Gz-402
Boston, MA 02215Phone+1 617-667-5864Fax+1 617-667-1604- Is this information wrong?
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2004
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
The Warren Alpert Medical School of Brown UniversityClass of 1997
Certifications & Licensure
MA State Medical License 1999 - 2024
Publications & Presentations
PubMed
- 751 citationsEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a rand...Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F. Weinstein, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Magnus Aurivillius, Vikt...> ;Lancet. 2016 Oct 29
- 820 citationsBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomi...J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T Ferguson, William W. Busse, Peter Barker, Stephanie Sprou...> ;Lancet. 2016 Oct 29
- 44 citationsEffect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United StatesJennifer L. Taylor-Cousar, Minoo Niknian, Geoffrey Gilmartin, Joseph M. Pilewski> ;Journal of Cystic Fibrosis. 2016 Jan 1
- Join now to see all
Press Mentions
Summary of Parent Organized NPS Zoom PanelAugust 8th, 2020
Organoid-Based Personalized Medicine Trial Enrollment CompleteFebruary 28th, 2020
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic FibrosisFebruary 24th, 2020- Join now to see all
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
